Pharvaris: Buy Rating Based on Strong Financial Position and Promising Trial Milestones

Pharvaris has been given a Buy rating by JonesTrading analyst Debanjana Chatterjee due to promising trial milestones and a strong financial position. The company is approaching a pivotal moment with the RAPIDe-3 trial update and is progressing in the Ph3 CHAPTER-3 prophylaxis study and the Ph3 CREAATE study. Pharvaris's strong cash position provides a solid financial runway into 2027, and their treatment has a strategic advantage in capturing market share from less effective therapies. Chatterjee is a 4-star analyst with a 19.3% average return and a 59.72% success rate. Citizens JMP has also maintained a Buy rating with a $52.00 price target.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, has reported its second-quarter 2025 financial results and provided updates on its clinical trials. The company's strong financial position and promising trial milestones have led to a Buy rating from JonesTrading analyst Debanjana Chatterjee.

Financial Results

Pharvaris reported a cash position of €200 million as of June 30, 2025, extending its cash runway into the first half of 2027. The company also announced a $201 million public offering, which will be used to fund late-stage clinical programs, hiring a sales and marketing team, and general corporate purposes [1].

The second quarter saw an increase in research and development (R&D) expenses to €29.6 million, up from €23.1 million in the same period last year. General and administrative (G&A) expenses were €10.8 million, a slight decrease from €11.3 million in the prior year. The company reported a loss for the quarter of €45.5 million, resulting in a basic and diluted loss per share of €0.83 [1].

Clinical Trial Updates

Pharvaris is approaching a pivotal moment with the anticipated topline results of the RAPIDe-3 trial, which is expected in the fourth quarter of 2025. This Phase 3 study is evaluating deucrictibant immediate-release capsule for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents [1].

Enrollment continues in the CHAPTER-3 study, a Phase 3 trial of deucrictibant extended-release tablet for prophylaxis against angioedema attacks. Topline results are expected in the second half of 2026. Additionally, the CREAATE study, which assesses deucrictibant for both prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) attacks, is expected to initiate by the end of 2025 [1].

Analyst Ratings

Analyst Debanjana Chatterjee from JonesTrading has given Pharvaris a Buy rating, citing promising trial milestones and a strong financial position. Chatterjee is a 4-star analyst with a 19.3% average return and a 59.72% success rate. Citizens JMP has also maintained a Buy rating with a $52.00 price target [1].

Conclusion

Pharvaris's strong financial position and the progress in its clinical trials position the company well for the future. With a solid cash runway and promising trial results on the horizon, investors should closely monitor the upcoming data releases from the RAPIDe-3 and CHAPTER-3 studies.

References

[1] Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update. (2025, August 12). Globe Newswire. Retrieved from https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-second-quarter-2025-financial-results-and